Therapeutic agents for achondroplasia

Details Therapeutic agents for achondroplasia Therapeutic agents for achondroplasia

A - Human Necessities

61

K

A61K 38/22 (2006.01) A61K 48/00 (2006.01)

Patent

CA 2398030

The present invention aims to provide novel therapeutic agents for achondroplasia caused by mutations in FGFR3. Therapeutic agents for achondroplasia caused by the cartilage growth inhibition resulting from mutations in the gene for fibroblast growth factor receptor 3 (FGFR3), comprising a substance activating guanylyl cyclase B (GC-B) as an active ingredient are disclosed.

Affiliated with

Also associated with

Rating

Therapeutic agents for achondroplasia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic agents for achondroplasia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents for achondroplasia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1745464